MYC and breast cancer: This is the first study to establish miR-32-5p → FBXW7 → c-MYC as a regulatory axis in breast cancer. While miR-32-5p targets BMP5 in colorectal cancer [37] and PTEN in myeloma [41], its role in stabilizing c-MYC via FBXW7 degradation is unique to breast malignancy and offers subtype-specific therapeutic potential.